GLP-1 Receptor Agonists and Joint Health

The primary objective of this research was to synthesise the current state of knowledge regarding the multi-faceted effects of glucagon-like peptide-1 (GLP-1) receptor agonists (RA) on the musculoskeletal system. By evaluating their impact on osteoarthritis (OA), osteoporosis, sarcopenia, intervertebral disc degeneration, and low back pain, this work highlights a therapeutic potential that extends far beyond metabolic regulation. GLP-1 receptors are not merely localised to the gut or brain; they are actively expressed within the synovial joint and in spinal tissues. When these receptors are activated, they initiate a cascade that reduces inflammatory signalling, mitigates oxidative stress, and suppresses the production of catabolic enzymes in chondrocytes and potentially other cell types in the joint. In preclinical models of OA, GLP-1 RAs have demonstrated the ability to attenuate cartilage degradation and preserve subchondral bone architecture. 1,2 Clinically, the weight reduction associated with these medications correlates strongly with decreased knee pain and enhanced joint function, though a notable gap persists in research that integrates advanced imaging with biochemical markers to confirm these structural benefits.